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Abstract
Intestinal lymphatic drug delivery has been widely studied because drugs can bypass the first-pass metabolism in
the liver via the lymphatic route, which increases oral bioavailability. Various lipid-based nanoparticles have been
used to deliver hydrophobic drugs to the lymphatic pathway. This review focuses on the liposomal delivery systems
used for intestinal lymphatic drug transport. Liposomal formulations have attracted particular attention because
they can stimulate the production of chylomicrons and the incorporated drugs readily associate with enterocyte-
derived chylomicrons, enhancing lymphatic drug transport. We believe that a full understanding of their contribution
to intestinal drug translocation will lead to effective oral delivery with liposomal formulations.
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Background
There are many ways to deliver drugs into the body, in-
cluding oral, pulmonary, subcutaneous, intravenous,
transdermal, and nasal. Among them, oral drug delivery
is particularly useful because it is convenient and com-
fortable for patients and thus is associated with a high
rate of compliance. In other words, patients prefer drugs
to be administered in oral form. However, orally admin-
istered drugs typically show low bioavailability due to
their degradation by enzymes in the gastrointestinal (GI)
tract, the difficulty of absorbing them in the small intes-
tine, and the first-pass metabolism in the liver [1]. After
oral administration, the drugs pass through the small in-
testine and enter the portal vein or intestinal lymphatic
system (Fig. 1). Two main factors control the route that
drugs take: molecular mass and solubility [2, 3]. Soluble,
small drugs are preferentially transported via the portal
vein. These drugs immediately accumulate in the liver
and are then metabolized by enzymes, which lowers the
drug concentration in the bloodstream. An alternative
route for delivering drugs to the systemic circulation is
the intestinal lymphatic pathway. Lipophilic drugs are
known to be transported via the lymphatic system. The
intestinal lymphatic pathway can bypass first-pass
metabolism in the liver, thus increasing drug bioavail-
ability. Furthermore, the co-administration of drugs
with lipids can enhance their lymphatic transport [4].
In a postprandial state, lipid–drug conjugates and
lipid-based nanoparticles have been widely studied for
the delivery of lipophilic drugs via the lymphatic
pathway. In this article, we highlight liposomal formu-
lations developed to facilitate the lymphatic transport
of loaded lipophilic drugs.
Overview of intestinal lymphatic drug transport
Assembly and secretion of chylomicrons
Chylomicrons are one group of lipoproteins. They con-
sist of triglycerides (85–92%), phospholipids (6–12%),
cholesterol (1–3%), and proteins (1–2%). Lipoproteins
are macromolecules that transport hydrophobic lipids
throughout the aqueous environment of the circulatory
system [3, 5]. Orally administered exogenous lipids are
absorbed into the apical side of enterocytes. Some
monoglycerides and fatty acids diffuse into enterocytes
and enter the portal vein, while others are resynthesized
to chylomicrons and secreted into lymphatic vessels. In
the process of chylomicron formation, monoglycerides
and fatty acids are transformed to triglycerides by either
the α-glycerol-3 phosphate pathway in the rough endo-
plasmic reticulum or the 2-monoglyceride pathway in
the smooth endoplasmic reticulum [3, 6, 7]. Triglycer-
ides synthesized by these two pathways then enter the
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endoplasmic reticulum lumen and are assembled into
chylomicrons. These chylomicrons are transported to
the Golgi and exocytosed from the enterocyte. Finally,
the chylomicrons enter the lymphatic route and circulate
throughout the body.
The lipid transport pathway varies depending on the
lipid class, lipid-chain length, and degree of saturation
(Fig. 2). Fatty acids with a chain length of 14 carbons or
more are transported via the lymphatic pathway, while
those with short chain lengths, which are more soluble,
are transported via portal blood. Unsaturated fatty acids
are also prone to be transported via the lymphatic path-
way. Thus, these unsaturated and longer-chain fatty
acids are assembled into larger lipoprotein chylomicrons
and enter the intestinal lymphatic pathway [3, 8]. After
the chylomicrons are exocytosed from the small intes-
tine, they enter lymphatic vessels and transport dietary
fats from the small intestine to peripheral tissues includ-
ing muscle, adipose tissues, and heart. Triglycerides in
chylomicrons are hydrolyzed by lipoprotein lipases to
glycerol and fatty acids at the inner surface of capillaries
in the peripheral tissues [9]. These chylomicron rem-
nants are also taken up by liver cells by interacting with
specific receptors in the liver.
Incorporation of lipophilic drugs into chylomicrons for
lymphatic transport
Drugs can be transported into systemic circulation by
either the portal vein or the lymphatic system. The parti-
tion coefficient (P) is the ratio of concentrations of a
drug in two immiscible solutions, octanol and water.
The log P value is a measure of drug lipophilicity. This
value can thus be used to determine the transport path-
way of drugs. Specifically, if the log P value of drugs is
higher than 5, the drugs are highly lipophilic. It has been
reported that lipophilic drugs associate with lipoproteins,
specifically within their core [3, 6]. Lipoproteins associ-
ated with lipophilic drugs enter intestinal lymphatic
vessels and are transported to systemic circulation. Co-
administration with lipids can increase the level of drug
transport through the intestinal lymphatic system (Fig. 3);
Fig. 1 Two pathways (portal vein versus lymph) of oral drug transport to systemic circulation
Fig. 2 Pathways of lipid absorption and chylomicron synthesis within enterocytes
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thus, several approaches for the co-administration of
lipophilic drugs with lipids have been studied (Table 1).
Postprandial state (diet-derived)
Chylomicron levels in the intestinal lymphatic duct in-
crease substantially after a meal or feeding on fatty food.
Fatty food enhances intestinal lipoprotein synthesis and
the access of drugs to the intestinal lymphatic system.
When drugs are co-administered with fatty food, their
lymphatic transport increases dramatically. Shui-Mei
Khoo et al. investigated the antimalarial drug halofan-
trine regarding intestinal lymphatic delivery [10]. The
lymphatic transport of halofantrine accounted for 1.3%
and 54% of the administered dose after fasting and in a
postprandial state, respectively, suggesting that a post-
prandial state is the main factor influencing lymphatic
halofantrine transport. More recently, Murakami et al.
showed that, in a postprandial state, vitamin E–siRNA
complex was administered by direct injection in a ligated
loop of the large intestine and delivered delivered by the
chylomicron-mediated lymphatic pathway [11]. Lipopro-
tein lipase changed the form from chylomicrons to
chylomicron remnants, which finally accumulated in the
liver. The siRNA delivered to the liver silenced apolipo-
protein B gene expression.
Lipid-conjugated drugs
Drugs modified with a lipid moiety, such as a fatty acid,
glyceride, or phospholipid, show increased lipophilicity
(Fig. 4). These lipid-conjugated drugs can be associated
into enterocyte-derived chylomicrons. However, such
modified drugs should be considered as novel entities
because this modification could raise problems of safety
and toxicity. In addition, confirmation should be ob-
tained that lipid-conjugated drugs show efficacy identical
or similar to that of the original drug [1, 12, 13].
Gert Fricker et al. used a phospholipid–valproic acid
conjugate as a model drug for oral delivery [13].
Fig. 3 Lipophilic drug transport mechanisms by association with lipoproteins
Table 1 Methods for incorporation of lipophilic drugs into chylomicrons






more than those of treating
any other methods.
Uncontrollable method [10] – [14]
Lipidic prodrugs Drugs are covalently bound
to a lipid moiety (fatty acid,
glyceride, phospholipid).
Through covalent bonding
with lipids, lipophilicity of
drugs can be increased.
- Pharmaceutically inert




Administration of a single
capsule of long-chain lipid
can stimulate significant
lymphatic transport of drugs.





- Effective carriers for drugs
- Stimulators of chylomicron
production
The effect of the formulation on
drug absorption and lymphatic
transport is less clear.
[13] – [18]
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Phospholipid–drug conjugates have been shown to en-
hance the absorption and bioavailability of oral drugs.
The absorption of this conjugate was examined in rats
by administering long-chain or medium-chain triglycer-
ide formulations. It was found that the bioavailability of
the conjugates was enhanced when conjugates were ad-
ministered with long-chain triglyceride formulations.
Drug lipophilicity increases by conjugation with the
phospholipid, resulting in enhanced absorption into
enterocytes. Arik Dahan et al. showed that phospho-
lipid–drug conjugates have been associated with chylo-
microns and reach the systemic circulation via the
lymphatic pathway [15]. An example of using drug–gly-
ceride conjugates to improve oral delivery has been also
reported [16]. Specifically, mefenamic acid was modified
with glyceride to reduce its side effects in the GI tract.
The biolabile prodrugs of mefenamic acid showed higher
plasma concentrations than upon treatment with the
parent drug. These lipidic prodrugs thus increase bio-
availability and reduce side effects in the GI tract.
Lipid-based nanoparticles (formulation-derived)
The administration of a single capsule of long-chain
lipids can stimulate significant lymphatic transport of
drugs. Exogenous lipids from various formulations en-
hance lymphatic transport by assembling into chylomi-
crons for endogenous lipid transport. Thus, drugs
together with exogenous lipids can be delivered more ef-
ficiently to the intestinal lymphatic system through an
increase in chylomicrons. Suzanne M. Caliph et al.
showed lipid-based nanoparticles with long-chain lipids
increased the oral bioavailability of lipophilic drugs [17].
Other studies reported that docetaxel nanocapsules con-
sisting of long-chain triglycerides were transported in
the form of lipoproteinated nanocapsules [18, 19]. These
nanocapsules were recognized as triglyceride-rich parti-
cles in enterocytes, which resulted in them being trans-
ported through the intestinal lymphatic pathway.
Chylomicron-mimicking carriers have also been devel-
oped to enhance the intestinal lymphatic pathway [20].
Carriers made of Compritol 888 ATO and soybean PC
were recognized as chylomicrons in enterocytes. Metho-
trexate loaded in the carriers was delivered efficiently to
the systemic circulation via the lymphatic route.
Liposomal formulations for lymphatic drug
transport
Liposomes are spherical vesicles formed by one or sev-
eral kinds of lipid with an aqueous phase inside and be-
tween the lipid bilayers [21–23]. Hydrophilic molecules
can be loaded into the interior of liposomes, and hydro-
phobic or lipophilic molecules into the lipid bilayer
(Fig. 5). Compared with other lipid-based nanoparticles,
liposomes have the ability to encapsulate and protect
drugs and to increase their absorption into enterocytes.
Liposomes can protect labile drugs from denaturation by
the harsh conditions in the GI tract. Lipids of liposomes
can also be utilized to stimulate the production of chylo-
microns in enterocytes, thus enhancing drug transport
Fig. 4 Types of lipidic prodrug: a fatty acids, b glycerides and c phospholipids
Fig. 5 Liposomes with a hydrophilic drug a encapsulated in the
aqueous core and a hydrophobic drug b incorporated into
the membrane
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into the lymphatic system. Furthermore, enterocyte up-
take of liposomes can be controlled with their size;
smaller showed higher uptake [24]. Therefore, this sec-
tion mainly focuses on liposomal formulations for oral
drug delivery, especially lymphatic drug transport.
Improvement of stability and bioavailability of drugs by
liposomal formulations
Liposomal drugs have several advantages over free
drugs for oral delivery. Liposomal formulations protect
drugs from harsh conditions and slow down the rate of
enzymatic degradation in the GI tract, thus improving
drug stability and bioavailability [25, 26]. Kisel et al.
showed that liposomes composed of phosphatidyletha-
nol had capability to protect the incorporated drugs
from pancreatic phospholipase [27]. Liposomal encap-
sulation also enhances the oral bioavailability of poorly
absorbed hydrophilic drugs. Sharon Sheue Nee Ling et
al. demonstrated increase in the oral bioavailability of
cefotaxime, a hydrophilic drug, with liposomal formula-
tions [28]. In addition, the liposomal formulation pro-
moted lymphatic transport of cefotaxime. Cefotaxime
concentrations in the lymph and plasma are higher when
administered with liposomal formulations than when
administered with an aqueous solution. These findings
demonstrate that liposomal formulations can play an im-
portant role in improving drug stability and bioavailability
for oral delivery, by facilitating lymphatic drug transport.
Improvement of liposome absorption into enterocytes
Liposome formulations have been engineered by several
methods to increase the efficiency of their uptake into
enterocytes. First, surfactants such as bile salts can be
incorporated into liposomes to enhance cellular uptake
by disrupting the apical side of enterocytes [29, 30]. Bile
salts incorporated into liposomes stabilize the liposo-
mal membrane from bile acids in the GI tract. In
addition, bile salt-incorporating liposomes show a pro-
longed residence time compared with conventional li-
posomes that incorporated cholesterol instead of bile
salts. Second, elastic liposomes are taken up more effi-
ciently by enterocytes [31]. Liposomes with Tween 80
and ethanol show elastic properties. These elastic lipo-
somes exhibit good stability in simulated gastric and in-
testinal fluids, and sustained release of the incorporated
drug. In oral delivery, elastic liposomes encapsulating
(+)-catechin show an increased plasma level of (+)-cat-
echin compared with free (+)-catechin. In addition, the
modification of liposomes with Pluronic F127 can en-
hance their mucus penetration and cellular uptake [32].
Pluronic F127-incorporating liposomes also show more
efficient delivery of coumarin 6 to enterocytes than un-
modified liposomes.
Effect of surface charge of liposomes on intestinal
lymphatic drug transport
Modifying the surface charge of liposomal membranes
increases cellular uptake and lymphatic drug transport.
The residence time of liposomal formulations in the GI
tract influences drug bioavailability. To increase the GI
residence time, the surface charge of liposomes was
engineered by coating them with carbopol or chitosan
[33–35]. Chitosan and carbopol have mucoadhesive
properties due to their positive charges. Therefore, a car-
bopol or chitosan coating improves the enteral absorp-
tion of liposomal drugs. In addition, in a recent study,
liposomes were prepared with cationic stearylamine
(SA), anionic phosphatidylserine (PS), or chitosan (CS)
[36] and subjected to a mucoadhesion experiment. The
liposomes prepared with SA showed better mucoadhe-
sion than those prepared with PS and CS. This suggests
that the positive charge of liposomes increases their
mucoadhesion, resulting in enhanced intestinal lymph-
atic drug delivery.
Conclusions
When drugs are orally administered, they can bypass
first-pass metabolism through the lymphatic pathway.
During intestinal lymphatic drug transport, long-chain
and unsaturated lipids are assembled into chylomicrons
in enterocytes. These chylomicrons are then exocytosed
from the cell and enter the lymphatic route. If lipophilic
drugs are co-administered with these lipids, they are
prone to incorporation into chylomicrons and can be de-
livered to the lymphatic system in the form of chylo-
micron–drug complexes. Thus, co-administration with
lipids can enhance the lymphatic transport of lipophilic
drugs. There are several methods to enhance such
lymphatic drug transport: administration during a post-
prandial state and the use of lipidic prodrugs and lipid-
based nanoparticles. In particular, liposomes, which are
the lipid-based nanoparticles most commonly used in
drug delivery, have advantages over other methods in in-
testinal lymphatic drug transport because they can de-
liver various lipophilic drugs efficiently to enterocytes
and utilize their phospholipids to stimulate the forma-
tion and exocytosis of chylomicron–drug complexes.
Further research is needed to elucidate the effects of
liposomal components on the formation and exocyt-
osis of chylomicron–drug complexes in intestinal
lymphatic delivery.
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